A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis
Details
Age
Adult
Type of Study
Treatment
Locations
Outpatient CTRC
Principal Investigator
Thomas Ragole, MD
Study ID
Protocol Number: 22-1813
More information available at ClinicalTrials.gov: NCT05218096
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers